August 22, 2017 / 10:06 PM / in a year

Sarepta Therapeutics defeats investor lawsuit on appeal

A federal appeals court on Tuesday upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading investors about the likelihood that its flagship treatment for a rare muscle disorder would gain regulatory approval.

The 1st U.S. Circuit Court of Appeals in Boston ruled that investors suing the Cambridge-based biopharmaceutical company had failed to allege facts that could lead to an inference that Sarepta and its executives intended to defraud shareholders.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below